{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:03Z","timestamp":1791295503894,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.09.030","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T22:27:15Z","timestamp":1380320835000},"page":"5798-5805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review"],"prefix":"10.1016","volume":"31","author":[{"given":"Ellen","family":"Rafferty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Yactayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.09.030_bib0005","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0010","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0015","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2006.01.009","article-title":"Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil","volume":"24","author":"Engel","year":"2006","journal-title":"Vaccine"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2013.09.030_bib0020","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0025","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.09.030_bib0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced age a risk factor for illness temporally associated with yellow fever vaccination","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.09.030_bib0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.030_bib0040","first-page":"244","article-title":"Age-related risk of adverse events following yellow fever vaccination in Australia","volume":"28","author":"Lawrence","year":"2004","journal-title":"Commun Dis Intell"},{"issue":"25","key":"10.1016\/j.vaccine.2013.09.030_bib0045","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.030_bib0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2013.09.030_bib0055","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune response during adverse events after 17D-derived yellow fever vaccination in Europe","volume":"197","author":"Bae","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0060","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease","volume":"25","author":"Belsher","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","article-title":"Yellow fever vaccine-associated viscerotropic disease and death in Spain","volume":"36","author":"Doblas","year":"2006","journal-title":"J Clin Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2013.09.030_bib0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.SMJ.0000157537.11806.DC","article-title":"Rare case of fatal yellow fever vaccine-associated viscerotropic disease","volume":"98","author":"Gerasimon","year":"2005","journal-title":"South Med J"},{"issue":"3","key":"10.1016\/j.vaccine.2013.09.030_bib0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1708-8305.2008.00209.x","article-title":"Yellow fever-associated viscerotropic disease in Barcelona, Spain","volume":"15","author":"Mu\u00f1oz","year":"2008","journal-title":"J Travel Med"},{"issue":"4","key":"10.1016\/j.vaccine.2013.09.030_bib0080","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1086\/590187","article-title":"Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES Genes","volume":"198","author":"Pulendran","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0085","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"issue":"9296","key":"10.1016\/j.vaccine.2013.09.030_bib0090","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(01)06914-8","article-title":"Effects of yellow fever vaccination","volume":"358","author":"Adhiyaman","year":"2001","journal-title":"Lancet"},{"issue":"9296","key":"10.1016\/j.vaccine.2013.09.030_bib0095","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(01)06917-3","article-title":"Effects of yellow fever vaccination","volume":"358","author":"Werfel","year":"2001","journal-title":"Lancet"},{"issue":"44","key":"10.1016\/j.vaccine.2013.09.030_bib0100","first-page":"989","article-title":"Adverse events associated with 17D-derived ywllow fever vaccination\u2014United States, 2001\u20132002","volume":"51","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-17","key":"10.1016\/j.vaccine.2013.09.030_bib0105","first-page":"1","article-title":"Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002","volume":"51","author":"Cetron","year":"2002","journal-title":"MMWR Recomm Rep"},{"issue":"9276","key":"10.1016\/j.vaccine.2013.09.030_bib0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine","volume":"358","author":"Chan","year":"2001","journal-title":"Lancet"},{"issue":"17-18","key":"10.1016\/j.vaccine.2013.09.030_bib0115","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.vaccine.2004.01.026","article-title":"Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX","volume":"22","author":"Kitchener","year":"2004","journal-title":"Vaccine"},{"issue":"9276","key":"10.1016\/j.vaccine.2013.09.030_bib0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"issue":"9276","key":"10.1016\/j.vaccine.2013.09.030_bib0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"issue":"9296","key":"10.1016\/j.vaccine.2013.09.030_bib0130","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/S0140-6736(01)06916-1","article-title":"Effects of yellow fever vaccination","volume":"358","author":"Troillet","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2013.09.030_bib0135","article-title":"Yellow fever vaccine associated viscerotropic disease in a young woman: a rare complication of a common vaccine","volume":"35","author":"Kennedy","year":"2007","journal-title":"Crit Care Med"},{"issue":"45","key":"10.1016\/j.vaccine.2013.09.030_bib0140","first-page":"1","article-title":"A death associated with yellow fever vaccination reported in Spain","volume":"8","author":"Agencia Espa\u00f1ola del Medicamentos y Productos Sanitarios edit by Eurosurveillance editorial team","year":"2004","journal-title":"Eurosurveillance"},{"issue":"4","key":"10.1016\/j.vaccine.2013.09.030_bib0145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4269\/ajtmh.2010.09-0570","article-title":"Case report: a case of yellow fever vaccine-associated viscerotropic disease in Ecuador","volume":"82","author":"Douce","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.vaccine.2013.09.030_bib0150","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3201\/eid1009.040197","article-title":"Genetic divergence and dispersal of yellow fever virus, Brazil","volume":"10","author":"Vasconcelos","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.09.030_bib0155","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1017\/S0950268804002602","article-title":"Risk of fatal adverse events associated with 17DD yellow fever vaccine","volume":"132","author":"Struchiner","year":"2004","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0160","unstructured":"Breugelmans G, Lewis R, Perea W, Niedrig M, Gessber B, Yactayo S, et al. Yellow fever adverse events following immunization in Africa: development of a standardized database for analysis and presentation of safety data. Version prior to print."},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.030_bib0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.provac.2010.07.012","article-title":"Yellow fever vaccine post-marketing surveillance in Brazil","volume":"2","author":"de Menezes Martins","year":"2010","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.vaccine.2013.09.030_bib0170","unstructured":"PAHO\/WHO statement. Investigation of serious adverse events in Peru following receipt of yellow fever vaccine produced by Bio-Manguinhos, Brazil. 21 March 2008."},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.030_bib0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.030_bib0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.vaccine.2004.05.018","article-title":"Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast","volume":"23","author":"Fitzner","year":"2004","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2013.09.030_bib0185","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vaccine.2013.09.030_bib0190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"20","key":"10.1016\/j.vaccine.2013.09.030_bib0195","first-page":"201","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 \u2013 conclusions and recommendations","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T13:00:54Z","timestamp":1564146054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":39,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X13012711"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 World Health Organization (WHO). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}